Surgical treatment of age-related macular degeneration: will there be a role in the future?

Clin Exp Ophthalmol. 2007 Mar;35(2):167-73. doi: 10.1111/j.1442-9071.2006.01410.x.

Abstract

Surgical treatment has been shown to be able to improve vision that is lost as a result of age-related macular degeneration. Surgery is complex, such that improvement has always to be weighed against risk of complications. The availability of Ranibizumab and Bevacizumab is set to dramatically alter our management options. Surgical treatment will have a limited role to play in the next few years.

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • Cost of Illness
  • Humans
  • Macular Degeneration / economics
  • Macular Degeneration / etiology
  • Macular Degeneration / surgery*
  • Ophthalmologic Surgical Procedures / trends*
  • Ranibizumab
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Bevacizumab
  • Ranibizumab